Breast Cancer Clinical Trial
— 351Official title:
BrUOG 351: Pre-Operative Accelerated Partial Breast Irradiation (APBI) Using Non-Invasive Image-Guided Breast Brachytherapy (NIBB)
NCT number | NCT03437915 |
Other study ID # | BrUOG 351 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2019 |
Est. completion date | January 21, 2020 |
Verified date | March 2021 |
Source | Brown University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Partial breast irradiation is typically performed after surgical removal of the tumor. Partial breast irradiation allows for focused radiation to the area from which the cancer was removed, sparing breast tissue from the potential bad effects of radiation compared to radiating the whole breast, which was the standard of care for many years. This study is evaluating the use of partial breast irradiation with NIBB performed before surgery instead of after surgery.This should allow researchers to target the cancer even more accurately and result in less normal breast tissue receiving radiation which may cause less side effects and/or a better cosmetic outcome. In this study partial breast treatment will be given with NIBB in 5 treatments over about 1 week. Surgical removal of the tumor will then be performed between 4-12 weeks following radiation treatment. Researchers believe that participant's risk of complications from surgery will not be higher after getting these radiation treatments than it would have been if participants had surgery first, but that is one of the things researchers are studying.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 21, 2020 |
Est. primary completion date | January 21, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Confirmed histological diagnosis of invasive breast carcinoma and/or DCIS (Invasive lobular carcinoma excluded); - Age greater or equal to 60 years old; - Life expectancy > 6 months; - Candidate for breast conserving surgery who intends to undergo breast conserving surgery as confirmed in writing by treating physician in consultation with surgeon - Clinically lymph node negative (cN0) as confirmed in writing by patient's treating physician. If patient has suspicious lymphadenopathy on imaging it is required that patient undergo a biopsy to confirm cN0. - Tumor size by imaging = 2cm; (Tis or T1) - Estrogen receptor positive if invasive disease (DCIS can be ER negative); - Her2neu negative if invasive disease; - Nuclear Grade 1 or 2 if invasive disease (DCIS can be Grade 3); - ECOG performance status of 0-2 (Appendix 1); - Informed consent signed. Exclusion Criteria: - Excisional biopsy or ipsilateral breast surgery within 6 months; - Invasive lobular histology; - Definitive LVSI on biopsy; - Suspicious imaging findings suggesting multi-focal or multi-centric disease, unless biopsy proven benign; - Paget's disease of the nipple - Distant metastases; - Known BRCA 1/2 Mutation - Active lupus or scleroderma,; - Psychiatric or addictive disorder that would preclude attending follow-up; - Neoadjuvant chemotherapy or endocrine therapy (adjuvant therapy is permitted); - Breast Implants; - Tumor not well visualized on AccuBoost imaging; - Breast separation with compression > 8cm at time of simulation. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jaroslaw Hepel | Brown University, Rhode Island Hospital, Women and Infants Hospital of Rhode Island |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of APBI including rate of surgical complications. | Surgery will occur 4-12 weeks post NIBB treatment | ||
Primary | Toxicity of pre-op APBI including rate of surgical complications. | Defined as acute (during treatment and through 4 weeks post treatment) | Defined at up to 6 weeks post APBI | |
Primary | Toxicity of surgical complications | Surgery to occur 4-12 weeks post radiation and post-op complications collected through 3 months post surgery | ||
Secondary | Assess and report late toxicity | Late toxicity defined as 6 weeks post NIBB through 3 years in follow-up | 6 weeks post treatment through 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |